StockTipsArenaBeta

BUY Aurobindo Pharma — Jay Thakkar, ICICI Securities

BUYAurobindo Pharma
Aurobindo Pharma share price target & all analyst calls

byJay Thakkar, ICICI SecuritiesHorizon: NA (inferred Intraday)21 Sept 2026, 12:14 pm ISTvia Zee Business (Live)

Entry₹1,731Inferred
Target₹1,775
Total upside +2.54% (call closed)
Stop loss₹1,699-1.85% risk
At expiry₹1,71221 Sept 2026, 3:05 pm
Expired-1.10%
Follow Jay Thakkar for new callsGet alertsWatch AUROPHARMA for new buy/sell callsGet alerts

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

Frozen at close · 21 Sept 2026
6 supporting0 opposing
Supports the BUY call (6)

2 advisors have active swing BUY calls on this stock, all issued in the last 14 days

Advisor consensus · adjacent horizon·21 Sept · today

JM Financial sees up to 28% upside in Dr Reddy’s and Aurobindo Pharma. Should you buy?

NewsEt-Markets·16 Sept · 5d ago

(opens in new tab)

Aurobindo Pharma Gets First USFDA Nod For First Metered-Dose Inhaler

NewsNdtv-Profit·15 Sept · 5d ago

(opens in new tab)

Aurobindo Pharma gets US FDA nod to sell first metered-dose asthma inhaler in US

NewsCnbc-Tv18·15 Sept · 6d ago

(opens in new tab)

Aurobindo Pharma received final US FDA approval for its Beclomethasone Dipropionate HFA Inhalation Aerosol in 40 mcg and 80 mcg strengths.

BSE · Company Update·15 Sept · 6d ago

(opens in new tab)
Neutral / worth noting (0)

Nothing found in this tip’s window yet.

Weighs against the BUY call (0)

Nothing found in this tip’s window yet.

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Aurobindo Pharma

All analyst calls on Aurobindo Pharma

More from Jay Thakkar, ICICI Securities

Every call and its outcome